Interim Results (Part 3 of 3)

AstraZeneca PLC
26 July 2007

AstraZeneca Development Pipeline
26 July 2007


Line Extensions


       Compound                 Mechanism           Area under investigation   Phase        Estimated Filing
                                                                                            MAA           NDA
Cardiovascular
Atacand                angiotensin II antagonist    diabetic retinopathy        III         2009          2009
Atacand Plus           angiotensin II antagonist /  32/12.5 mg, 32/25 mg for    III         2H 2008
                       thiazide diuretic            hypertension
Crestor                statin                       atherosclerosis             III       Approved        Filed
Crestor                statin                       outcomes CHF                III        1H 2008       1H 2008
Crestor                statin                       outcomes End Stage Renal    III         2009          2009
                                                    Disease
Gastrointestinal
Nexium                 proton pump inhibitor        NSAID GI side effects -     III      Promotable*      Filed
                                                    symptom resolution
Nexium                 proton pump inhibitor        NSAID GI side effects -     III       Launched        Filed
                                                    ulcer healing
Nexium                 proton pump inhibitor        peptic ulcer bleeding       III        1H 2008       1H 2008
Nexium Sachet          proton pump inhibitor        GERD                        III         Filed       Launched
formulation
Nexium                 proton pump inhibitor        extra-oesophageal reflux    II         >2009**       >2009**
                                                    disease
Nexium low dose        proton pump inhibitor        low dose aspirin            III                       2009
aspirin combination                                 associated peptic ulcer

Neuroscience
Seroquel XR            D2/5HT2 antagonist           schizophrenia               III         Filed       Approved
Seroquel               D2/5HT2 antagonist           bipolar maintenance         III        Q4 2007        Filed
Seroquel               D2/5HT2 antagonist           bipolar depression          III        Q4 2007      Approved
Seroquel XR            D2/5HT2 antagonist           generalised anxiety         III        2H 2008       1H 2008
                                                    disorder
Seroquel XR            D2/5HT2 antagonist           major depressive            III        2H 2008       1H 2008
                                                    disorder
Seroquel XR            D2/5HT2 antagonist           bipolar mania               III        1H 2008       1H 2008

Seroquel XR            D2/5HT2 antagonist           bipolar depression          III        1H 2008       Q4 2007

Oncology & Infection
Faslodex               oestrogen receptor           1st line advanced breast    III         >2009         >2009
                       antagonist                   cancer
Faslodex               oestrogen receptor           adjuvant                    III         >2009         >2009
                       antagonist
FluMist (MedImmune)    live, attenuated, intranasal influenza                   III        1H 2008        Filed
                       influenza virus vaccine

* Authorities stated these symptoms were already captured within the GERD label.
Text stating 'No clinical interaction with naproxen or rofecoxib' was approved.

**Project Extraesophageal reflux disease (reflux asthma) will be completed but
will not result in a regulatory filing.


Line Extensions (continued)


       Compound                  Mechanism           Area under investigation   Phase        Estimated Filing
                                                                                            MAA           NDA
Respiratory & Inflammation
Symbicort Turbuhaler   inhaled steroid/fast onset,   Symbicort Maintenance       III      Launched
                       long-acting ss2 agonist       and Reliever Therapy for
                                                     asthma (SMART)
Symbicort pMDI         inhaled steroid/fast onset,   asthma                      III       Filed*      Launched**
                       long-acting ss2 agonist

Symbicort pMDI         inhaled steroid/fast onset,   COPD                        III       Filed*       1H 2008
                       long-acting ss2 agonist

* To be supplemented in 2008 with data supporting two additional strengths
** US approval based on 12 years and above


NCE's

Phase III


       Compound                  Mechanism                 Area under          Phase        Estimated Filing
                                                          investigation
                                                                                             MAA          NDA
Cardiovascular
AZD6140                ADP receptor antagonist       arterial thrombosis        III        >2009        >2009
Saxagliptin            dipeptidyl peptidase-4        diabetes                   III          2009      1H 2008
                       (DPP-4) inhibitor
Dapagliflozin          sodium-glucose                diabetes                   III        >2009        >2009
                       cotransporter-2 (SGLT2)
                       inhibitor
Oncology & Infection
Zactima                VEGF/EGF TKI inhibitor with   NSCLC                      III       2H 2008      2H 2008
                       RET kinase activity

Recentin               VEGF signalling inhibitor     NSCLC and CRC             II/III      >2009        >2009
                       (VEGFR-TKI)
Recentin               VEGF signalling inhibitor     recurrent glioblastoma     III        >2009        >2009
                       (VEGFR-TKI)
ZD4054                 endothelin A receptor         hormone resistant          III        >2009        >2009
                       antagonist                    prostate cancer
Motavizumab            humanized monoclonal antibody RSV prevention             III         2009       4Q 2007
(MedImmune)


NCE's

Phases I and II


       Compound                  Mechanism           Area under investigation   Phase       Estimated Filing
                                                                                             MAA         NDA
Cardiovascular
Crestor/fibrate        statin + fibrate fixed        dyslipidaemia                II                     2009
                       combination
AZD0837                thrombin inhibitor            thrombosis                   II        >2009       >2009
AZD1175                                              diabetes/obesity             I         >2009       >2009
AZD2207                                              diabetes/obesity             I         >2009       >2009
AZD1305                antiarrhythmic                arrhythmias                  I         >2009       >2009
AZD6370                                              diabetes                     I         >2009       >2009
AZD4121                cholesterol absorption        dyslipidaemia                I         >2009       >2009
                       inhibitor
Gastrointestinal
AZD9056                ion channel blocker (P2X7)    inflammatory bowel           II        >2009       >2009
                                                     disease
AZD3355                inhibitor of transient lower  GERD                         II        >2009       >2009
                       oesophageal sphincter
                       relaxations  (TLESR)
Neuroscience
PN-400                 naproxen + esomeprazole       signs and symptoms of OA     II        >2009        2009
                                                     and RA

AZD3480                neuronal nicotinic receptor   cognitive disorders in       II        >2009       >2009
                       agonist                       schizophrenia
AZD3480                neuronal nicotinic receptor   Alzheimers                   II        >2009       >2009
                       agonist
AZD2327                enkephalinergic receptor      anxiety & depression         I         >2009       >2009
                       modulator
AZD5904                enzyme inhibitor              multiple sclerosis           I         >2009       >2009
AZD1080                                              Alzheimers                   I         >2009       >2009
AZD3783                                              anxiety and depression       I         >2009       >2009

AZD3241                                              Parkinson's disease          I         >2009       >2009

AZD6765                                              depression                   I         >2009       >2009

AZD0328                                              Alzheimers                   I         >2009       >2009

AZD1940                                              nociceptive and              I         >2009       >2009
                                                     neuropathic pain


Phases I and II (continued)


Oncology & Infection
Zactima                VEGF/EGF TKI inhibitor with   medullary thyroid           II         2009         2009
                       RET kinase activity           cancer

CytoFab                anti-TNF-alpha polyclonal     severe sepsis               II         >2009       >2009
                       antibody
AZD6244                MEK inhibitor                 solid tumours               II         >2009       >2009
(ARRY-142886)
CAT-3888               recombinant immunotoxin hairy hairy cell leukemia         II         >2009       >2009
                       cell
AZD2281                PARP inhibitor                breast cancer               II         >2009       >2009
EBV vaccine*                                         PTLD                        II                     >2009

(MedImmune)
AZD0530                SRC kinase inhibitor          solid tumours and           I          >2009       >2009
                                                     haematological
                                                     malignancies
AZD1152                aurora kinase inhibitor       solid tumours and           I          >2009       >2009
                                                     haematological
                                                     malignancies
AZD4769                                              solid tumours               I          >2009       >2009
AZD4877                                              solid tumours               I          >2009       >2009
AZD8931                                              solid tumours               I          >2009       >2009
AZD7762                                              solid tumours               I          >2009       >2009
AZD8330                MEK inhibitor                 solid tumours               I          >2009       >2009
(ARRY-424704)
CAT-8015               recombinant immunotoxin       haematological              I          >2009       >2009
                                                     malignancies
AZD2836 (Arrow)                                      hepatitis C                 I          >2009       >2009
MEDI-534 (MedImmune)   RSV/PIV-3 vaccine             intranasal immunisation     I                      >2009
MEDI-560 (MedImmune)   PIV-3 vaccine                 intranasal immunisation     I                      >2009
H5N1 (MedImmune)                                     pandemic influenza          I           TBA         TBA
                                                     vaccine
MEDI-524 (Motavizumab) MAb targets F-Protein         early & late treatment      I                      >2009
(MedImmune)                                          of disease in paeds > 1
                                                     yr
MEDI-561 (MedImmune)   HSP 90 inhibitor              solid tumours               I                      >2009
MEDI-538  (MedImmune)  CD19 B cells                  leukemia/lymphoma           I                      >2009
MEDI-564               F protein inhibitor           RSV treatment               I                      >2009

(MedImmune)


*Partnered products

Phases I and II (continued)


Respiratory & Inflammation
AZD9056                ion channel blocker (P2X7)    rheumatoid arthritis        II         >2009       >2009
AZD1981                                              asthma                      II         >2009       >2009
AZD5672                                              rheumatoid arthritis        II         >2009       >2009
MEDI-528  (MedImmune)  anti-IL-9 antibody            asthma                      II                     >2009
AZD4818                                              COPD                        I          >2009       >2009
CAT-354                anti-IL-13 antibody           asthma                      I          >2009       >2009
AZD5904                                              COPD                        I          >2009       >2009
AZD1744                                              COPD                        I          >2009       >2009
AZD1236                                              COPD                        I          >2009       >2009
AZD9668                                              COPD                        I          >2009       >2009
MEDI-563  (MedImmune)  anti-IL-5R antibody           asthma                      I                      >2009
MEDI-545  (MedImmune)  humanised antibody            SLE, Myositis               I                      >2009
Pneumococcal vaccine *                               streptococcus               I                      >2009
(MedImmune)                                          pneumoniae


* Partnered products

NCE's

Pre Clinical


       Compound                  Mechanism                 Area under          Phase        Estimated Filing
                                                          investigation
                                                                                             MAA          NDA
Cardiovascular
AZD8593                                              haemostasis                 PC        >2009        >2009
AZD1283                                              thrombosis                  PC        >2009        >2009
AZD5861                                              dyslipidaemia               PC        >2009        >2009
AZD1656                                              diabetes/obesity            PC        >2009        >2009
AZD3988                                              diabetes/obesity            PC        >2009        >2009
AZD3118                                              arrhythmias                 PC        >2009        >2009

Gastrointestinal
AZD2066                                              GERD                        PC        >2009        >2009
AZD5329                                              functional GI disease       PC        >2009        >2009

Neuroscience
AZD3102                                              Alzheimers                  PC        >2009        >2009
AZD8797                                              multiple sclerosis          PC        >2009        >2009
AZD2066                                              analgaesia                  PC        >2009        >2009
AZD6280                                              anxiety                     PC        >2009        >2009
AZD2624                                              schizophrenia               PC        >2009        >2009
AZD1386                                              analgaesia                  PC        >2009        >2009
AZD3043                GABA-A receptor modulator     short acting                PC        >2009        >2009
                                                     anaesthetic
AZD7903                                              analgaesia                  PC        >2009        >2009
AZD1704                                              analgaesia                  PC        >2009        >2009
AZD7325                                              anxiety                     PC        >2009        >2009


Pre Clinical (continued)


Compound                         Mechanism                 Area under          Phase        Estimated Filing
                                                          investigation
                                                                                             MAA          NDA
Oncology & Infection
AZD9935                VEGF signalling inhibitor     solid tumours               PC        >2009        >2009
                       (VEGFR-TKI)
AZD0424                SRC kinase inhibitor          solid tumours               PC        >2009        >2009
AZD5180                anti-angiogenic               solid tumours               PC        >2009        >2009
AZD1845                                              solid tumours               PC        >2009        >2009
AZD9468                                              solid tumours               PC        >2009        >2009
AZD2932                                              solid tumours               PC        >2009        >2009
CAT-5001               recombinant immunotoxin       solid tumours               PC        >2009        >2009
AZD6918                                              solid tumours               PC        >2009        >2009
AZD4992                                                                          PC        >2009        >2009
AZD5099                                              infection                   PC        >2009        >2009
AZD1480                                              range of tumours            PC        >2009        >2009
AZD6302                                              MRSA                        PC        >2009        >2009
AZD8055                                              range of tumours            PC        >2009        >2009
AZD7295 (Arrow)                                      hepatitis C                 PC        >2009        >2009
AZD6495                                              range of tumours            PC        >2009        >2009
MEDI-557 (MedImmune)   YTE - extended half-life RSV  RSV Prophylaxis             PC                     >2009
                       MAb
Respiratory & Inflammation
AZD6067                protease inhibitor            COPD                        PC        >2009        >2009
AZD6357                                              osteoarthritis              PC        >2009        >2009
AZD3825                                              asthma                      PC        >2009        >2009
AZD5069                                              COPD                        PC        >2009        >2009
AZD8848                                              asthma                      PC        >2009        >2009
AZD8075                                              asthma                      PC        >2009        >2009
AZD6605                                              osteoarthritis              PC        >2009        >2009
CAM-3001                                             rheumatoid arthritis        PC        >2009        >2009
AZD3199                                              asthma/COPD                 PC        >2009        >2009


MedImmune Pre Clinical


Compound                         Mechanism                 Area under          Phase        Estimated Filing
                                                          investigation
                                                                                             MAA          NDA
Oncology & Infection
MEDI-536               hMPV/PIV-3 vaccine            respiratory infection       PC                     >2009
hMPV MAb               hMPV MAb                      respiratory infection       PC                     >2009
MEDI-552               anti-CD20                     leukemia/lymphoma           PC                     >2009
MEDI-548               anti-EphB4 MAb                solid tumours               PC                     >2009
MEDI-549               anti-Ephrin B2 MAb            solid tumours               PC                     >2009
MEDI-555               anti-cMet                     solid tumours               PC                     >2009
MEDI-544               anti-EphA2 BiTE               solid tumours               PC                     >2009
MEDI-562               hedgehog inhibitor            solid tumours               PC                     >2009
MEDI-551               anti-CD19 MAb                 leukemia/lymphoma           PC                     >2009
MEDI-547               anti-EphA2 conj               solid tumours               PC                     >2009
anti CEA BiTE          anti-CEA BiTE                 solid tumours               PC                     >2009
PIV-1 vaccine          PIV-1 vaccine                 respiratory infection       PC                     >2009
PIV-2 vaccine          PIV-2 vaccine                 respiratory infection       PC                     >2009
anti staph HP MAb      anti-staph HP MAb             infectious disease          PC                     >2009
hMPV vaccine           hMPV vaccine                  infectious disease          PC                     >2009
anti Candida HP MAb    anti-Candida HP MAb           infectious disease          PC                     >2009

Respiratory & Inflammation
MEDI-546               anti-IFNaR MAb                inflammation                PC                     >2009
MEDI-541               anti-HMGB-1 MAb               inflammation                PC                     >2009
MEDI-551               anti-CD19 MAb                 inflammation                PC                     >2009
MEDI-552               anti-CD20 MAb                 inflammation                PC                     >2009
MEDI-553               anti-CD22 MAb                 inflammation                PC                     >2009
anti IL6 MAb           anti-IL6 MAb                  inflammation                PC                     >2009
anti RAGE MAb          anti-RAGE MAb                 inflammation                PC                     >2009
anti ICOS MAb          anti-ICOS MAb                 inflammation                PC                     >2009
anti YKL40 MAb         anti-YKL40 MAb                asthma/COPD                 PC                     >2009
anti Chitinase MAb     anti-Chitinase MAb            asthma/COPD                 PC                     >2009
anti C5a MAb           anti-C5a MAb                  inflammation                PC                     >2009


AstraZeneca Development Pipeline
Discontinued Projects vs 1 February 2007 FY


Cardiovascular & Gastrointestinal
    NCE/Line Extension                  Compound                 Area under investigation
NCE                         AZD2479                          dyslipidaemia
NCE                         AZD9684                          thrombosis
NCE                         AGI-1067                         atherosclerosis
LE                          Seloken/Toprol-XL                HCTZ combination
NCE                         AZD6610                          dyslipidaemia



Neuroscience
    NCE/Line Extension                  Compound                 Area under investigation
NCE                         AZD9272                          neuropathic pain
NCE                         AZD6538                          neuropathic pain


Oncology & Infection
    NCE/Line Extension                  Compound                 Area under investigation
NCE                         AZD5896                          solid tumours
NCE                         AZD3646                          solid tumours & haematological
                                                             malignancies
LE                          Iressa BC                        breast cancer
NCE                         AZD1689                          solid tumours
NCE (MedImmune)             MEDI-507 (siplizumab) *          PTCL/CTCL
NCE (MedImmune)             MEDI-553 (anti CD22) *           leukemia/lymphoma
NCE (MedImmune)             MEDI-542*                        solid tumours
NCE (MedImmune)             MEDI-556*                        solid tumours
LE (MedImmune)              Synagis **                       RSV



Respiratory & Inflammation
    NCE/Line Extension                  Compound                 Area under investigation
NCE                         AZD7928                          COPD
NCE                         AZD6703                          rheumatoid arthritis
NCE                         AZD1678                          asthma
NCE                         AZD2392                          asthma
NCE                         AZD9215                          asthma

* Compound entered the pipeline in April 07, but has since been discontinued
** Minor activity ongoing, but will not lead to new indication/formulation


Comments

As disclosure of compound information is balanced by the business need to
maintain confidentiality, information in relation to some compounds listed here
has not been disclosed at this time.

Compounds in development are displayed by phase.

Abbreviations:


PC -  Pre-clinical: Candidate Drug accepted for development but not yet
      administered to man.
MAA - Marketing Authorisation Application (Europe).
NDA - New Drug Application/Biologics Licensing Application (USA).


                      This information is provided by RNS
            The company news service from the London Stock Exchange